NDC 60219-2279 – Everolimus
Everolimus 2 mg/1 · Tablet, For Suspension · Oral
Product NDC60219-2279
Product details
- Brand name
- Everolimus
- Generic name
- Everolimus
- Labeler
- Amneal Pharmaceuticals NY LLC
- Dosage form
- Tablet, For Suspension
- Route
- Oral
- Marketing category
- ANDA · ANDA218863
- Marketed since
- January 14, 2025
- Listing expires
- December 31, 2027
- Pharmacologic class
- Kinase Inhibitor; mTOR Inhibitor Immunosuppressant
Active ingredients
- Everolimus 2 mg/1
Package NDC codes (1)
| Package NDC | Description | Since |
|---|---|---|
| 60219-2279-2 | 4 BLISTER PACK in 1 CARTON (60219-2279-2) / 7 TABLET, FOR SUSPENSION in 1 BLISTER PACK (60219-2279-1) | Jan 14, 2025 |
Other Everolimus products
- 60219-2280 Everolimus 3 mg/1 · Tablet, For Suspension · Amneal Pharmaceuticals NY LLC
- 60219-2281 Everolimus 5 mg/1 · Tablet, For Suspension · Amneal Pharmaceuticals NY LLC
- 70377-090 Everolimus 2 mg/1 · Tablet, For Suspension · Biocon Pharma Inc.
- 70377-092 Everolimus 5 mg/1 · Tablet, For Suspension · Biocon Pharma Inc.
- 70377-091 Everolimus 3 mg/1 · Tablet, For Suspension · Biocon Pharma Inc.
- 51991-990 Everolimus 2 mg/1 · Tablet, For Suspension · Breckenridge Pharmaceutical, Inc.
- 51991-992 Everolimus 5 mg/1 · Tablet, For Suspension · Breckenridge Pharmaceutical, Inc.
- 51991-991 Everolimus 3 mg/1 · Tablet, For Suspension · Breckenridge Pharmaceutical, Inc.
- 17088-0247 Everolimus 2 mg/1 · Tablet, For Suspension · Novartis Pharma Stein AG
- 17088-0114 Everolimus 5 mg/1 · Tablet, For Suspension · Novartis Pharma Stein AG
- 17088-0107 Everolimus 3 mg/1 · Tablet, For Suspension · Novartis Pharma Stein AG
- 67877-721 Everolimus 1 mg/1 · Tablet · Ascend Laboratories, LLC